[New preparation with antalgic sedative and anxiolytic activity in manifestations of interest to internal medicine. Double-blind controlled clinical study].
A controlled double-blind clinical trial using randomised blocks was carried out on 3 groups of 10 patients with internal diseases and a pain syndrome accompanied by anxiety. One group received the product under examination (FC 35aA) and the other two its components (dipotassic chlorazepate, paracetamol and codeine). FC 35aA gave the best results, pointing to synergism between its components. Increase of the pain threshold and of the actual involvement of the patient was achieved to an extent that the single components could not match when administered individually at the same doses.
D000082:Acetaminophen / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000700:Analgesics / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003009:Clorazepate Dipotassium / Q000627:therapeutic use*; D003061:Codeine / Q000627:therapeutic use; D004338:Drug Combinations; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy
D000700:Analgesics; D014151:Anti-Anxiety Agents; D004338:Drug Combinations; D000082:Acetaminophen; D003009:Clorazepate Dipotassium; D003061:Codeine
Su di un nuovo preparato ad attività antalgico-sedativa ed ansiolitica in manifestazioni di interesse internistico. Ricerca clinica controllata "double blind"